



**UNICHEM**  
**LABORATORIES LTD.**

Fax No : 91 (22) 2678 4391 / 5198  
Tel. No. : 91 (22) 66888333  
Website : <http://www.unichemlabs.com>  
CIN : L99999MH1962PLC012451.

**Registered & Corporate Office :** Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102, INDIA.

March 9, 2016

Ref: Stock-exchange/2015-16

Department of Corporate Services  
Bombay Stock Exchange Ltd.  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001

Mr. Hari K  
Asst. Vice President - Operations  
National Stock Exchange of India Ltd  
Exchange Plaza, Bandra – Kurla Complex  
Bandra (East), Mumbai – 400 051

Dear Sir,

**Ref: BSE Scrip Code -506690 : NSE Symbol – UNICHEMLAB**  
**Sub: Disclosures under Reg. 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.**

Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release pertaining to receipt of ANDA approval from United States Food and Drug Administration (U.S. FDA) for Quetiapine Fumarate Tablets, 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg.

Please take this on record.

Thank you,

Yours Faithfully,  
**For UNICHEM LABORATORIES LIMITED**

**NEEMA THAKORE**  
*Head – Legal & Company Secretary*

*C:\Users\admin\Downloads\stockex (2).doc*



**UNICHEM**  
LABORATORIES LTD.

## **UNICHEM LABORATORIES LIMITED**

Unichem Bhavan  
Prabhat Estate, Off S.V.Road,  
Jogeshwari (West),  
Mumbai - 400 102.  
Tel. No: +91 (22) 66 888 333  
Fax. No: +91 (22) 267 843 91/ 5198  
CIN: L99999MH1962PLC012451

### **Press Release**

**Mumbai, Wednesday March 9, 2016**

#### **Unichem Laboratories receives ANDA approval from USFDA for Quetiapine Fumarate Tablets**

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (USFDA) for Quetiapine Fumarate Tablets.

*Quetiapine Fumarate Tablets* 25mg, 50mg, 100mg, 200mg, 300mg and 400mg are therapeutically equivalent to Seroquel Tablets, 25mg, 50mg, 100mg, 200mg, 300mg and 400mg of *AstraZeneca Pharmaceuticals LP*.

Quetiapine Fumarate is an atypical antipsychotic indicated for the treatment of Schizophrenia. Quetiapine Fumarate is also indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex and for maintenance treatment as an adjunct to lithium or divalproex. It is also indicated as a monotherapy for the acute treatment of depressive episodes associated with bipolar disorder.

The product will be commercialized from Unichem's Ghaziabad plant. Active Pharmaceutical Ingredient will also be made in house at Pithampur API Plant.

Unichem Laboratories Limited now has total of 21 ANDA approvals from USFDA.



**UNICHEM  
LABORATORIES LTD.**

**About Unichem Laboratories Limited**

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms. More information about the company can be found at [www.unichemlabs.com](http://www.unichemlabs.com)

**For more information please contact:**

Ms. Neema Thakore

Ph: +91-22-66888 404

E-mail: [neema.thakore@unichemlabs.com](mailto:neema.thakore@unichemlabs.com)

Mr. Rakesh Parikh/ Mr. Monish Shah

Ph: +91-22-66888 414

Ph: +91-22-66888 509

E-mail: [rparikh@unichemlabs.com](mailto:rparikh@unichemlabs.com)

[monish.shah@unichemlabs.com](mailto:monish.shah@unichemlabs.com)

***Disclaimer:** This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.*